The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Functional cure with earlier cilta-cel treatment in relapsed multiple myeloma
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses emerging evidence for functional cure in patients with relapsed multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel). He highlights the International Myeloma Society (IMS) definition of functional cure, incorporating sustained progression-free survival (PFS) without treatment, confirmed measurable residual disease (MRD) negativity and negative imaging, and notes increasing rates of patients meeting these criteria with earlier use of cilta-cel. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We just had a session here at the IMS meeting about cure and the new definition of the International Myeloma Society of a functional cure is five years progression-free survival without any treatment, achieving an MRD-negative state which has been confirmed and also being imaging negative. And we know with cilta-cel in CARTITUDE-1, which is a median of six prior lines of therapy, 33% achieve this functional cure...
We just had a session here at the IMS meeting about cure and the new definition of the International Myeloma Society of a functional cure is five years progression-free survival without any treatment, achieving an MRD-negative state which has been confirmed and also being imaging negative. And we know with cilta-cel in CARTITUDE-1, which is a median of six prior lines of therapy, 33% achieve this functional cure. And as I indicated before, now with CARTITUDE-2, which is one to three prior lines of therapy, this increases to 50%. So I think with cilta-cel, with a BCMA-directed CAR T-cell therapy, we have the option of a functional cure in patients even with relapsed multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
